



FRIDAY 14 AUGUST 2026			
0700 - 1900	Registration Open - Level 2, Foyer 1		
0800 - 1900	Industry Exhibition Open - Melbourne Room 1		
0800 - 1000	Conference Opening & Multidisciplinary Plenary & Patrick C Walsh Lecture		
Room	Melbourne Room 2		
Chairs	Dr Phil Dundee & Dr Fairleigh Reeves		
0800-0805	Conference Opening Dr Phil Dundee - Convenor		
0805-0825	Balancing early detection, overdiagnosis and efficient use of healthcare resources Associate Professor Anna Lantz		
0825-0845	Re-defining clinically significant prostate cancer - challenging the dogma Associate Professor Kara Watts		
0845-0905	Active Surveillance in 2026: Imaging-guided patient selection and follow-up Associate Professor Giorgio Gandaglia		
0905-0925	What do our patients want us to talk about? Issues of intimacy and sexuality in prostate cancer Dr Amanda Hordern		
0925-0945	Patrick C Walsh Lecture Radioligand therapy 2026: Initial developments and future concepts Professor Oliver Sartor		
0945-1000	Question & Answer/Discussion		
1000 - 1030	Morning Tea & Industry Exhibition - Melbourne Room 1		
1030 - 1230	Clinical Urology Session 1A	1030-1230	Nursing & Allied Health Session 1B
Theme	Screening, biomarkers and population health & Rapid Fire Presentations	Theme	Precision medicine: The changing landscape of prostate cancer detection, diagnosis & focal therapy
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
Chairs	Associate Professor Jeremy Grummet & Dr Nader Awad	Chairs	Ms Evie Mertens & Ms Rachel Heerey
1030-1050	Implementing PSA screening programs – real-world lessons from a preparatory program Associate Professor Anna Lantz	1030-1050	Beyond PSA – emerging biomarkers for prostate cancer in Australia Associate Professor Matthew Roberts

1050-1110	PSA screening in modern practice – who, when, how? Associate Professor Kara Watts	1050-1110	From Guidelines to Practice: Applying the 2026 Australian early detection of prostate cancer recommendations Professor David Smith
1110-1130	Australian perspective – 2026 Guidelines on Risk adapted testing, MRI and Active surveillance Professor Peter Heathcote	1110-1130	Introducing a Nurse-Led TP biopsy service Ms Debbie Victor
1130-1150	Biomarkers in screening - Stockholm3 and beyond Associate Professor Anna Lantz	1130-1150	The future in a surveillance society Professor Niall Corcoran
1150-1210	Imaging as a biomarker - bypassing biopsy Associate Professor Matthew Roberts	1150-1210	The emerging role of focal therapy in prostate cancer. patient selection, oncological outcomes, and functional results Associate Professor John Yaxley
1210-1215	<i>Rapid Fire Presentation</i> Prostate cancer risk after male breast cancer: a population based study and implications for targeted surveillance Mr Basil Razi	1210-1230	Salvage management after focal therapy failure Professor Jonathon Coleman
1215-1220	<i>Rapid Fire Presentation</i> Performance of MiCheck®Prostate MRI versus PHI in patients with a prior biopsy Dr Douglas Campbell		
1220-1225	<i>Rapid Fire Presentation</i> Prostate cancer prevention beyond pharmacology: An update on nutraceuticals and lifestyle interventions Ms Jacinta Bonaddio		
1230 - 1330	Lunch, Industry Exhibition & Poster Viewing - Melbourne Room 1		
1330 - 1530	Clinical Urology Session 2A Theme Imaging and risk stratification Room Melbourne Room 2 Chairs Associate Professor Marlon Perera & Associate Professor John Yaxley	1330-1530	Nursing & Allied Health Session 2B Theme Innovations in treatment of localised prostate cancer Room Meeting Room 203 & 204 Chairs Dr Jane Crowe & Ms Helen Crowe
1330-1350	MRI grey zones: Practical management of challenging cases Dr Peter Swindle	1330-1350	Innovations in surgery for prostate cancer Associate Professor Alvin Goh
1350-1410	GenI-AIRSPACE Professor Niall Corcoran	1350-1410	Standardized collection of complications after radical prostatectomy - "If you can't measure it, you can't improve it" Associate Professor Giorgio Gandaglia
1410-1430	Upgrading on AS: biology vs sampling error Associate Professor Kara Watts	1410-1430	Beaming on in 2026 - Shining the light on Radiotherapy Dr Ee Siang Choong
1430-1440	Low diagnostic yield of PSMA PET/CT in ISUP grade group 2/3 prostate cancer: A prospective multicentre analysis Ms Jacinta Bonaddio	1430-1450	Optimizing Quality of Life Post Prostate SBRT Professor Sean Collins
1440-1455	PSMA PET: staging, recurrence, and limitations Professor Rod Hicks	1450-1510	Managing misinformation, disinformation, and treatment regret in prostate cancer Dr Maria Ftanou
1455-1505	Near-Universal PSA response to stereotactic radiotherapy provides biological support for long axial field of view PSMA-PET/CT in identifying clinically relevant disease in biochemical recurrence of prostate cancer Dr Paul Conway	1510-1520	Robocare Patient-Directed Online Package (RoboPOP): A transitional modular approach to digital patient education pre-robot-assisted radical prostatectomy Mr Marc Diocera

1505-1525	Debate: Modern biopsy techniques: Target biopsy only Professor Jeremy Grummet Modern biopsy techniques: Systematic plus target biopsy Associate Professor Weranja Ranasinghe	1520-1530	Transperineal fiducial marker implantation under local anaesthetic in an outpatient setting: Safety and tolerability Ms Karen Kennedy
1530 - 1600	Afternoon Tea & Industry Exhibition - Melbourne Room 1		
1600 - 1730	Clinical Urology Session 3A Theme Robotic Prostatectomy in the Multi-Platform Era: Current Systems, Emerging Technologies Room Melbourne Room 2 Chairs Associate Professor Matt Roberts & Associate Professor Janelle Brennan	1600-1730	Nursing & Allied Health Session 3B Theme Managing the whole person: Quality of Life in Prostate Cancer Room Meeting Room 203 & 204 Chairs Ms Molly Lowther & Ms Shan Morrison
1600-1620	Improving robotic surgical performance through proficiency-based simulation training Associate Professor Alvin Goh	1600-1615	Eating Well with Prostate Cancer: Evidence, Myths, and the Supplement Question Dr Brenton Baguley
1620-1640	Standardized collection of complications after radical prostatectomy - "If you can't measure it, you can't improve it" Associate Professor Giorgio Gandaglia	1615-1630	Beyond the Expected: Pelvic floor physio case studies in prostate cancer care Ms Lauren Clarke
1640-1700	Can fluorescence enhanced intraoperative imaging improve radical prostatectomy? Associate Professor Alvin Goh	1630-1645	From evidence to action: having the exercise conversation with prostate cancer patients Professor Prue Cormie
1700-1720	Where do robotic platforms fit in the future of prostate cancer surgery? Professor Jonathon Coleman	1645-1715	Sex talk in clinical practice: Why is it so hard? Dr Amanda Hordern
1720-1730	Update on PCOR - where has the data gone and how do we measure national outcomes? Associate Professor Marlon Perera	1715-1730	Penis Potions: understanding intracavernosal formulations Ms Francesca Rogers
1730-1745	Hands-on experience featuring multiple robotic platforms & IMRA hydrogel models	1730- 1745	Question & Answer/Discussion
1745 - 1900	Industry Welcome Reception - Melbourne Room 1		

SATURDAY 15 AUGUST 2026			
0645 - 1730	Registration Open - Level 2, Foyer 1		
0700 - 0830	Navigating the new standard of systemic treatments in HSPC proudly supported by Astellas Room Meeting Room 203 & 204 Chairs A/Professor Matt Roberts		
Speakers	Dr Andrew Morton , Senior Urology Trainee, Royal Brisbane & Women's Hospital (RBWH), Brisbane Dr Louise Kostos , Consultant Medical Oncologist, Peter MacCallum Cancer Centre, Melbourne Ms Debbie Victor , Uro-Oncology Clinical Nurse Specialist, Royal Cornwall Hospitals NHS Trust, United Kingdom Professor Oliver Sartor , Medical Oncologist, East Jefferson General Hospital (EJGH) Cancer Center, United States		
0815 - 1615	Industry Exhibition Open - Melbourne Room 1		
0845 - 1045	Multidisciplinary Plenary Room Melbourne Room 2 Chairs Dr Paul Conway & A/Professor Anna Lantz		
0845-0905	The role of radical prostatectomy in locally advanced and oligometastatic disease Associate Professor Alvin Goh		
0905-0925	SBRT in Oligometastatic Prostate Cancer: Does Ablation Change Outcomes or Just Select Better Biology? Professor Sean Collins		

0925-0945	mCRPC: where do PARP inhibitors and combinations fit? Professor Oliver Sartor		
0945-1005	Outcomes in Focal Therapy: a Historical Perspective and Impact on Clinical Trial Design Associate Professor Kara Watts		
1005-1025	PIONEER & Big Data: the future of prostate cancer research Associate Professor Giorgio Gandaglia		
1025-1045	Question & Answer/Discussion		
1045 - 1115	Morning Tea & Industry Exhibition - Melbourne Room 1		
1115 - 1245	Clinical Urology Session 4A	1115 - 1245	Nursing & Allied Health Session 4B
Theme	Oligometastatic and locally advanced disease & Abstract Presentations	Theme	Prostate cancer in the outback & Abstract Presentations
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
Chairs	Dr Mario Guerrieri & Ms Fairleigh Reeves	Chairs	Adam Cuthbertson-Chin & Ms Evie Mertens
1115-1130	The role of PLND in the PSMA PET/CT era Associate Professor Giorgio Gandaglia	1115-1125	The influence of geography on prostate cancer outcomes Dr Natasha Roberts
1130-1145	Re-Irradiation: SBRT for Retreatment of Radiation Failures Professor Sean Collins	1125-1135	Bridging the gap: The medical oncology nurse practitioner role in regional prostate cancer care Mr Justin Hargreaves
1145-1200	Neoadjuvant therapy in prostate cancer Professor Niall Corcoran	1135-1145	Restoring intimacy after prostate cancer: A regional erectile dysfunction workshop Ms Gaylene Corbett
1200-1210	SABR for PSMA PET/CT staged, oligometastatic prostate cancer - A multicentre study Dr Gemma D'Adamo	1145-1155	Prostate cancer in the bush- keeping up with city slickers - a rural perspective in optimal patient care Mr Stu Wilder
1210-1220	SBRT versus converntionally frunctionated radiotherapy in localised prostate cancer: A systematic review of toxicity, efficacy and quality of life Dr Yonatan Adinata	1155-1215	Question & Answer/Discussion
1220-1230	Safety and functional outcomes of salvage RP following primary laser ablation for recurrent prostate cancer Dr Allen Guo	1215-1225	Transition from urology nurse to urology research nurse: role development and contribution to clinical trials Ms Chern Xuan Lee
1230-1240	National trends in pelvic lymph node dissection during radical prostatectomy from 1997 - 2024 Miss Annie Lee	1225-1235	The current practice of clinicians in managing prostate cancer patients on oral androgen receptor pathway inhibitors – a single specialist centre survey Mr Marc Diocera
1240-1245	Question & Answer/Discussion	1235-1245	Nurse-led innovation: embedding ePROMs in prostate cancer surveillance Ms Catherine White
1245 - 1345	Lunch, Industry Exhibition & Poster Viewing - Melbourne Room 1		
1345 - 1545	Clinical Urology Session 5A	1345 - 1545	Nursing & Allied Health Session 5B
Theme	Metastatic prostate cancer	Theme	Advancing advanced prostate cancer
Room	Melbourne Room 2	Room	Meeting Room 203 & 204
Chairs	Professor Jonathon Coleman & Dr Nick Mehan	Chairs	Mr Russell Briggs & Mr Marc Diocera
1345-1405	Should we treat the primary in metastatic disease? A medical oncologists perspective Professor Oliver Sartor	1345-1355	From Pipeline to Patient: How the Telix Portfolio Can Support Better Prostate Cancer Care Ms Simone Leyden
1405-1425	T-Cell Engagers - The final Frontier? Professor Ben Tran	1355-1415	Androgen receptor pathway inhibitor ARPi in metastatic castration sensitive prostate cancer Dr Shirley Wong
1425-1445	PRIMARY2 and BiPASS : Seeing more, biopsying less Associate Professor Matt Roberts	1415-1435	Keeping men healthy on doublet therapy Ms Debbie Victor

1445-1505	Safety and dosimetry of 177Lu-rosopatamab tetraxetan plus SoC in patients with metastatic castration-resistant prostate cancer: preliminary results from part 1 of phase 3 ProstACT global study Dr Aviral Singh	1435-1455	What's new and what's available in radioligand therapy in Australia 2026 Ms Elizabeth Medhurst
1505-1525	nmCRPC - yesterday, today and tomorrow Professor Ben Tran	1455-1515	Communicating with men with prostate cancer and their families about bad news – considerations in men centred care Ms Tracey Gardiner
1525-1535	<i>Rapid Fire Presentation</i> Real-world outcomes and tolerability of intranasal vardenafil in men with erectile dysfunction, including a large subgroup after prostate cancer treatment Ms Melissa Hadley Barrett	1515-1535	Hope for the best, prepare for the worst Ms Debbie Victor
1535-1545	Question & Answer/Discussion	1535-1545	Question & Answer/Discussion
1545 - 1615	Afternoon Tea & Industry Exhibition - Melbourne Room 1		
1615 - 1730	Multidisciplinary Plenary & Announcement of Abstract Awards & Conference Closing		
Room	Melbourne Room 2		
Chairs	Dr Cristian Udovicich and Dr Fred Bacchetta		
1615-1715	Management of PSMA avid pelvic nodal disease in the primary setting- Delphi consensus An APCC-led multidisciplinary expert consensus on the management of newly diagnosed PSMA node-positive but conventional imaging node-negative prostate cancer. Panellists – Professor Oliver Sartor, Professor Sean Collins, Professor Jonathon Coleman, Associate Professor Giorgio Gandaglia, Associate Professor Anna Lantz, Associate Professor Kara Watts & Professor Rod Hicks		
1715-1730	Presentation of Abstract Awards, Closing and Announcement of APCC 2027 Presentation of Abstract Awards – Ms Helen Crowe & Dr Phil Dundee Closing and Announcement of APCC 2027 – Dr Phil Dundee		
1900 - 2330	Conference Celebration - Evergreen, Crown		